The world's first terahertz spectrometer capable of making measurements in multiple sampling geometries combines reflective and transmission spectroscopy technology
TeraView , the company that launched the world's first commercial terahertz spectrometer, has announced the availability of what it says is the world's first terahertz spectrometer capable of making measurements in multiple sampling geometries, the Spectra 1000D.
Building on the success of the Spectra 1000, the latest addition to Teraview's terahertz spectroscopy portfolio combines reflective spectroscopy with its existing transmission spectroscopy technology.
The Spectra 1000D has already been ordered by leading pharmaceutical companies, and offers chemists and material scientists new flexibility in the presentation and analysis of polymorphic, crystalline and amorphous substances in the research and development cycle.
By offering both ATR and specular reflection sampling geometries in modular form, in addition to the existing transmission sampling, the user can choose the best measurement method for an extensive range of sample types, including liquids, powders, gels, creams, films and reflective surfaces.
With the new ATR module, the user can also select between germanium and silicon crystals, allowing spectroscopic information to be gathered from different depths from the sample surface.
TeraView's existing transmission spectroscopy capabilities have set the market parameters for the use of terahertz in the analysis of intermolecular relationships in the research and development cycle and have provided a new understanding of polymorphic behaviour, says the company.
"With the introduction of Terahertz reflectance spectroscopy, Teraview is continuing to deliver tools that offer immediate business benefits to the pharmaceutical industry," said John Paul Cerroti, VP sales and product development at Teraview.
"The Spectra 1000D enables faster and earlier insights into the polymorphic behaviour of drug candidates, which enables significant acceleration of the development process, giving attractive cost savings and speeding the production of high quality, stable drugs and medication."
